Biocompatibles has re-invented itself a third time, exiting traditional device markets for riskier drug-device convergence plays in oncology and stroke, clinical areas dominated by drug therapy. This
By Stephen Levin Convinced it was too far behind in drug-eluting stents, Biocompatibles sold its cardiovascular business and is now focusing on cancer, embarking on a repositioning that can be a rough